| Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China S Li, L Peng, C Tan, X Zeng, X Wan, X Luo, L Yi, J Li PloS one 15 (5), e0232240, 2020 | 21 | 2020 |
| First-line atezolizumab for metastatic NSCLC with high PD-L1 expression: a United States-based cost-effectiveness analysis Y Peng, X Zeng, L Peng, Q Liu, L Yi, X Luo, S Li, L Wang, S Qin, X Wan, ... Advances in therapy 38, 2447-2457, 2021 | 16 | 2021 |
| Cost-effectiveness of nivolumab plus ipilimumab combined with two cycles of chemotherapy as first-line treatment in advanced non-small cell lung cancer Y Peng, X Zeng, L Peng, Q Liu, L Yi, X Luo, S Li, L Wang, S Qin, X Wan, ... Advances in therapy 38 (7), 3962-3972, 2021 | 13 | 2021 |
| Sintilimab plus bevacizumab biosimilar versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysis Y Peng, X Zeng, L Peng, Q Liu, L Yi, X Luo, S Li, L Wang, S Qin, X Wan, ... Frontiers in Pharmacology 13, 778505, 2022 | 12 | 2022 |
| Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50% L Wang, Y Peng, X Zeng, L Peng, S Li, S Qin, X Wan, C Tan Advances in therapy 38 (8), 4354-4365, 2021 | 12 | 2021 |
| Cost-effectiveness of lorlatinib as a first-line therapy for untreated advanced anaplastic lymphoma kinase-positive non-small cell lung cancer SN Li, JH Li, LB Peng, YM Li, XM Wan Frontiers in Oncology 11, 684073, 2021 | 10 | 2021 |
| Cost-effectiveness of frontline treatment for advanced renal cell carcinoma in the era of immunotherapies SN Li, JH Li, LB Peng, YM Li, XM Wan Frontiers in Pharmacology 12, 718014, 2021 | 9 | 2021 |
| Cost-effectiveness of bevacizumab biosimilar LY01008 combined with chemotherapy as first-line treatment for Chinese patients with advanced or recurrent nonsquamous non-small … X Luo, Q Liu, Z Zhou, L Yi, L Peng, X Wan, X Zeng, C Tan, S Li Frontiers in Pharmacology 13, 832215, 2022 | 8 | 2022 |
| Cost-effectiveness of atezolizumab plus chemotherapy as first-line therapy for metastatic urothelial cancer S Qin, L Yi, S Li, C Tan, X Zeng, L Wang, Y Peng, X Wan Advances in Therapy 38 (6), 3399-3408, 2021 | 8 | 2021 |
| Cost-effectiveness of first-line versus second-line pembrolizumab or chemotherapy in patients with microsatellite-instability-high/mismatch repair-deficient advanced colorectal … T Chongqing, L Sini, Z Xiaohui, P Liubao, P Ye, Q Shuxia, W Liting, ... Frontiers in Pharmacology 12, 802942, 2021 | 7 | 2021 |
| Social connection and lifestyle factors associated with happiness in urban older adults in China: A cross-sectional study with a community sample J Liu, S Li, X Yan, J Li, Q Sun, H Mei, H Rao Research in gerontological nursing 16 (3), 147-160, 2023 | 6 | 2023 |
| Cost-effectiveness of avelumab maintenance therapy for advanced or metastatic urothelial carcinoma in the United States Y Peng, Z She, L Peng, Q Liu, L Yi, X Luo, S Li, L Wang, S Qin, X Wan, ... Advances in Therapy 38, 5710-5720, 2021 | 6 | 2021 |
| First-line daratumumab in addition to chemotherapy for newly diagnosed multiple myeloma patients who are transplant ineligible: a cost-effectiveness analysis SN Li, JH Li, LB Peng, CQ Tan, XH Zeng, CY Peng, C Zhang, YM Li, ... Clinical Therapeutics 43 (7), 1253-1264. e5, 2021 | 6 | 2021 |
| Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in China: A cost-effectiveness analysis based on a mapping algorithm derived from a Chinese population C Tan, S Li, L Yi, X Zeng, L Peng, S Qin, L Wang, X Wan Advances in Therapy 38, 2571-2585, 2021 | 6 | 2021 |
| First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis L Wang, Y Peng, S Qin, X Wan, X Zeng, S Li, Q Liu, C Tan Plos one 18 (4), e0279786, 2023 | 5 | 2023 |
| Clinical benefit and cost effectiveness of risk-stratified gastric cancer screening strategies in China: a modeling study S Qin, X Wang, S Li, C Tan, X Zeng, X Luo, L Yi, L Peng, M Wu, Y Peng, ... Pharmacoeconomics 40 (7), 725-737, 2022 | 5 | 2022 |
| Cost-effectiveness of triple therapy vs. biologic treatment sequence as first-line therapy for rheumatoid arthritis patients after methotrexate failure SN Li, JH Li, LB Peng, YM Li, XM Wan Rheumatology and Therapy 8, 775-791, 2021 | 5 | 2021 |
| Cost-effectiveness analysis of adding daratumumab to a regimen of bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma X Zeng, Q Liu, L Peng, Y Peng, L Yi, X Luo, S Li, X Wan, C Tan Advances in Therapy 38, 2379-2390, 2021 | 5 | 2021 |
| Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer J Xie, SN Li, YM Li, JH Li BMC Health Services Research 23 (1), 706, 2023 | 4 | 2023 |
| Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis C Tan, X Luo, S Li, L Yi, X Zeng, L Peng, S Qin, L Wang, X Wan Clinical Rheumatology 41, 63-73, 2022 | 4 | 2022 |
